论文部分内容阅读
目的:观察瑞格列奈联合甘精胰岛素治疗Ⅱ型糖尿病的效果。方法:选择86例Ⅱ型糖尿病患者,连续治疗观察12周,每周根据血糖调整剂量,在治疗前后测定空腹和餐后2 h血糖,糖化血红蛋白、血脂、血压、体重指数及低血糖发生率。结果:在治疗前后空腹血糖(FBG),餐后2 h血糖(PBG)及糖化血红蛋白(HbA1c),均有明显下降(P<0.01)。血脂中甘油三脂(TG)在治疗前后亦有统计学差异(P<0.05),而血压、体重指数在治疗前后无统计学意义(P>0.05)。有3例发生轻微低血糖。结论:在Ⅱ型糖尿病治疗中应用瑞格列奈联合甘精胰岛素可有效的降低血糖及糖化血红蛋白,且安全性高。
Objective: To observe the effect of repaglinide combined with insulin glargine on type Ⅱ diabetes mellitus. Methods: Eighty-six patients with type 2 diabetes mellitus were selected and treated continuously for 12 weeks. The fasting and postprandial blood glucose, glycosylated hemoglobin, blood lipid, blood pressure, body mass index and the incidence of hypoglycemia were measured before and after treatment according to the blood glucose adjusted dose. Results: Fasting plasma glucose (FBG), postprandial blood glucose (PBG) and HbA1c were significantly decreased before and after treatment (P <0.01). Serum triglyceride (TG) also had statistical difference before and after treatment (P <0.05), while blood pressure and body mass index had no statistical significance before and after treatment (P> 0.05). Slight hypoglycemia occurred in 3 patients. Conclusion: The application of repaglinide combined with insulin glargine can effectively reduce blood glucose and glycosylated hemoglobin in the treatment of type Ⅱ diabetes mellitus, and its safety is high.